Human coagulation factor VIII is available under the trade names Monoclate-P, Hemophil M, Koate DVI, Anti-hemophilic Factor (Human). This pharmaceutical medicine is indicated to treat hemorrhage which is caused by Hemophilia A. It is classified as Coagulation Factors or Hemostatic Coagulation Factor and is available in the strengths 250 IU, 500 IU, 1000 IU, and 1500 IU. It is administered through intravenous route in the form of reconstituted solution at 2ml/min, not higher than 10ml/min. This pharmaceutical medicine does not have any kind of mild, moderate, or severe kind of drug interactions listed yet. The side effects associated with this drug include headache, drowsiness, lethargy, blurred vision, chills, tachycardia, hives, hypersensitivity reaction, vomiting, and nausea. No study is available for its use in pregnant women but it should be used with caution and should only be used if necessarily needed. Its secretion into human breastmilk is unknown and should be used by lactating women only with the recommendation of a doctor. It is contraindicated in patients who are hypersensitive to this derived protein. During its administration screening for Tachycardia and Factor VIII is important. It was approved by the FDA on December 4, 2009, under the brand name Wilate, manufactured by Octapharma.

In response to certain injury it is activated and interacts with factor IX which causes certain chemical reactions to occur and a blood clot is formed.